-
公开(公告)号:US09752151B2
公开(公告)日:2017-09-05
申请号:US14779874
申请日:2014-03-27
发明人: Tae Won Kim , Dong Hoon Jin , Seung Woo Hong , Jai Hee Moon , Jae Sik Shin , Jin Sun Kim , Kyung Ah Jung , Jung Shin Lee , Eun Kyung Choi , Jae Lyun Lee , Yong Sang Hong , Kyu Pyo Kim , Ky Youb Nam , Bong Cheol Kim
IPC分类号: A01N43/52 , A61K31/415 , C12N15/113 , A61K31/4245 , C12Q1/68 , G01N33/50 , A23L33/13
CPC分类号: C12N15/1137 , A23L33/13 , A23V2002/00 , A61K31/4245 , C12N15/113 , C12N2310/11 , C12N2310/12 , C12N2310/122 , C12N2310/14 , C12N2310/531 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/5011
摘要: The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of PTEN and accordingly nuclear localization of PTEN is induced, as a result, an Akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express PTEN and NEDD4-1. Consequently, the p34 gene expression inhibitor or p34 protein activity inhibitor according to the present invention can be effectively used as a treatment agent or a metastasis suppression agent for cancers.
-
公开(公告)号:US20170327894A1
公开(公告)日:2017-11-16
申请号:US15329904
申请日:2015-07-29
申请人: THE ASAN FOUNDATION
发明人: Dong Hoon Jin , Seung Woo Hong , Jai Hee Moon , Jae Sik Shin , Seung Mi Kim , Dae Hee Lee , Eun Young Lee , Seul Lee
IPC分类号: C12Q1/68 , A61K31/404 , G01N33/574 , A61K31/713 , C12N15/113
CPC分类号: C12Q1/6886 , A61K31/404 , A61K31/7088 , A61K31/713 , C12N15/1138 , C12N2310/14 , C12N2310/141 , C12N2310/531 , C12N2320/31 , C12Q1/68 , C12Q2600/106 , C12Q2600/158 , C12Y207/10001 , G01N33/574 , G01N33/57492 , G01N2333/70503
摘要: The present invention relates to a novel biomarker for predicting susceptibility to an MET inhibitor, and a use thereof, and more specifically, the present invention provides: a biomarker for predicting susceptibility to the MET inhibitor, the biomarker comprising the Immunoglobulin Superfamily member 1 (IGSF1, NM_001555.2) gene; a composition for predicting susceptibility to the MET inhibitor, the composition comprising a pharmaceutical preparation for measuring the degree of expression of the gene in the biomarker, or the degree of expression of the protein of the gene; a pharmaceutical composition for treating diseases related to the dysregulation of the MET signaling pathway, the pharmaceutical composition comprising, as an active ingredient, an inhibitor inhibiting the expression of the gene in the biomarker, or the expression or activity of the protein of the gene; a kit for predicting susceptibility to the MET inhibitor, the kit comprising the compositions; and a method for predicting susceptibility to the MET inhibitor. According to the present invention, the present invention has an excellent effect of predicting susceptibility to the MET inhibitor for stomach cancer or lung cancer, and thus the present invention may be usefully employed for treating stomach cancer or lung cancer.
-
公开(公告)号:US11008622B2
公开(公告)日:2021-05-18
申请号:US15329942
申请日:2015-07-29
申请人: THE ASAN FOUNDATION
发明人: Tae Won Kim , Dong Hoon Jin , Seung Woo Hong , Jai Hee Moon , Jae Sik Shin , Seung Mi Kim , Dae Hee Lee , Eun Young Lee , Seul Lee , Yong Sang Hong
IPC分类号: C12Q1/6886 , C12Q1/68 , A61P43/00 , A61P35/00
摘要: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d'Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent. According to the present disclosure, since an effect of predicting the susceptibility to the EGFR-targeted agent is excellent in a colon cancer, the present disclosure may be useful in the treatment of the colon cancer.
-
4.
公开(公告)号:US20180327851A1
公开(公告)日:2018-11-15
申请号:US15742408
申请日:2016-07-06
申请人: THE ASAN FOUNDATION
发明人: Dong Hoon Jin , Seung Woo Hong , Jai Hee Moon , Jae Sik Shin , Seung Mi Kim , Dae Hee Lee , Eun Young Lee , Jung Shin Lee , Bong Choel Kim
IPC分类号: C12Q1/6886
摘要: The present invention relates to a method for determining sensitivity to a simultaneous inhibitor against poly ADP ribose polymerase (PARP) and Tankyrase. According to the present invention, a colorectal treatment effect can be maximized by sorting patients having sensitivity to the simultaneous inhibitor against PARP and Tankyrase.
-
公开(公告)号:US20190127802A1
公开(公告)日:2019-05-02
申请号:US15329942
申请日:2015-07-29
申请人: THE ASAN FOUNDATION
发明人: Tae Won Kim , Dong Hoon Jin , Seung Woo Hong , Jai Hee Moon , Jae Sik Shin , Seung Mi Kim , Dae Hee Lee , Eun Young Lee , Seul Lee , Yong Sang Hong
IPC分类号: C12Q1/6886 , A61P35/00 , A61P43/00
摘要: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d'Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent. According to the present disclosure, since an effect of predicting the susceptibility to the EGFR-targeted agent is excellent in a colon cancer, the present disclosure may be useful in the treatment of the colon cancer.
-
公开(公告)号:US10683553B2
公开(公告)日:2020-06-16
申请号:US15742408
申请日:2016-07-06
申请人: THE ASAN FOUNDATION
发明人: Dong Hoon Jin , Seung Woo Hong , Jai Hee Moon , Jae Sik Shin , Seung Mi Kim , Dae Hee Lee , Eun Young Lee , Jung Shin Lee , Bong Choel Kim
IPC分类号: C12Q1/68 , C12Q1/6886
摘要: The present invention relates to a method for determining sensitivity to a simultaneous inhibitor against poly ADP ribose polymerase (PARP) and Tankyrase. According to the present invention, a colorectal treatment effect can be maximized by sorting patients having sensitivity to the simultaneous inhibitor against PARP and Tankyrase.
-
-
-
-
-